tirzepatide gip/glp-1 Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Tirzepatide Molecule Dual Gip Glp-1

Khan, I.M

The forward-looking statements contained in this communication are made only as of March 18, 2026

After reaching your desired skin tone, reduce to 12 times weekly for maintenance

In the head-to-head DREAMS-3 study, glucagon/GLP-1 agonist mazdutide was more effective than GLP-1 agonist Ozempic (semaglutide) at reducing haemoglobin A1c levels, a marker for blood glucose control, and at helping subjects to lose weight

(Outlines contraindications for niacin therapy, including active peptic ulcer disease, active liver disease with elevated enzymes, hypersensitivity to niacin, and arterial bleeding, as well as monitoring recommendations for blood pressure, glucose, uric acid, etc., due to niacins systemic effects)